Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

How can drug discovery for psychiatric disorders be improved?

Abstract

Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd2217

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 81 references

Research works printed but not linked: 1

  1. O'Donnell, P. & Grace, A. A. in Review of Psychiatry Vol 18: Schizophrenia in a Molecular Age. Ed. Tamminga, C. A. 109–140 (American Psychiatric Press, Washington DC, 1999).

Cited by

See all 240

Metadata

Authors
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D.
Affiliations
  • Inserm (FR)
  • Rutgers, The State University of New Jersey (US)
  • University of South Florida (US)
  • National Hospital for Neurology and Neurosurgery (GB)
  • National Institutes of Health (US)
  • University of Pittsburgh (US)
  • University of Dundee (GB)
  • Emory University (US)
  • University of Milan (IT)
  • Centre National de la Recherche Scientifique (FR)
  • Karolinska Institutet (SE)
Corresponding author
Spedding, Michael
Venue
Nature Reviews Drug Discovery
Published
2007-03
Volume
6
Issue
3
Pages
189-201
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2039643193
Cited by
240
References
81
Citations by year
2026: 2 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 3 · 2015: 8 · 2014: 10 · 2013: 17 · 2012: 30
FWCI
2.73
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
psychiatric drug discovery, depression, schizophrenia, anxiety, neuropsychiatric disorders, neuroplasticity, translational neuroscience, multidisciplinary approach
MeSH terms
Mental Disorders, Consensus Statements as Topic, Humans, Models, Biological, Surveys and Questionnaires, Tranquilizing Agents, Drug Design, Signal Transduction, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How can drug discovery for psychiatric disorders be improved? https://app.cochat.ai/papers/10.1038/nrd2217
The paper
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D. (2007). How can drug discovery for psychiatric disorders be improved? Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd2217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.